JP2025121986A5 - - Google Patents
Info
- Publication number
- JP2025121986A5 JP2025121986A5 JP2025077691A JP2025077691A JP2025121986A5 JP 2025121986 A5 JP2025121986 A5 JP 2025121986A5 JP 2025077691 A JP2025077691 A JP 2025077691A JP 2025077691 A JP2025077691 A JP 2025077691A JP 2025121986 A5 JP2025121986 A5 JP 2025121986A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- polypeptide
- collagen
- linker
- binding domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962856468P | 2019-06-03 | 2019-06-03 | |
| US62/856,468 | 2019-06-03 | ||
| JP2021571671A JP7680375B2 (ja) | 2019-06-03 | 2020-06-03 | コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物 |
| PCT/US2020/070113 WO2020247974A1 (en) | 2019-06-03 | 2020-06-03 | Methods and compositions for treating cancer with collagen binding drug carriers |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571671A Division JP7680375B2 (ja) | 2019-06-03 | 2020-06-03 | コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025121986A JP2025121986A (ja) | 2025-08-20 |
| JP2025121986A5 true JP2025121986A5 (https=) | 2025-12-17 |
Family
ID=73652058
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571671A Active JP7680375B2 (ja) | 2019-06-03 | 2020-06-03 | コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物 |
| JP2025077691A Pending JP2025121986A (ja) | 2019-06-03 | 2025-05-08 | コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571671A Active JP7680375B2 (ja) | 2019-06-03 | 2020-06-03 | コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220298225A1 (https=) |
| EP (1) | EP3976111A4 (https=) |
| JP (2) | JP7680375B2 (https=) |
| CN (1) | CN114173822B (https=) |
| AU (1) | AU2020289485A1 (https=) |
| BR (1) | BR112021024438A2 (https=) |
| CA (1) | CA3144535A1 (https=) |
| MX (1) | MX2021014932A (https=) |
| WO (1) | WO2020247974A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2024177006A1 (https=) * | 2023-02-20 | 2024-08-29 | ||
| US12605394B2 (en) | 2024-07-25 | 2026-04-21 | Visionary Assets, Llc | Compositions containing cannabinoid nanoparticles |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4879236A (en) | 1984-05-16 | 1989-11-07 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5871986A (en) | 1994-09-23 | 1999-02-16 | The General Hospital Corporation | Use of a baculovirus to express and exogenous gene in a mammalian cell |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| DK1141028T3 (da) | 1998-12-23 | 2010-05-25 | Pfizer | Humane monoklonale antistoffer til CTLA-4 |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| KR101808751B1 (ko) * | 2009-11-13 | 2017-12-13 | 그리폴스 테라퓨틱스 인코포레이티드 | 폰 빌레브란트 인자(ｖＷＦ)-함유 제제, 및 그와 관련된 방법, 키트 및 용도 |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| WO2012112690A2 (en) * | 2011-02-16 | 2012-08-23 | Fabius Biotechnology | Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains |
| JP2014022858A (ja) | 2012-07-17 | 2014-02-03 | Murata Mfg Co Ltd | 電力増幅器 |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| JP6508785B2 (ja) * | 2013-10-25 | 2019-05-08 | ファーマサイクリックス エルエルシー | ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置 |
| EP3094650A2 (en) * | 2014-01-13 | 2016-11-23 | Pieris Pharmaceuticals GmbH | Multi-specific polypeptide useful for localized tumor immunomodulation |
| WO2016033331A1 (en) * | 2014-08-28 | 2016-03-03 | Bioatla, Llc | Conditionally active chimeric antigen receptors for modified t-cells |
| WO2016054107A1 (en) * | 2014-09-29 | 2016-04-07 | Counterpoint Biomedica Llc | Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polymers |
| WO2017106656A1 (en) * | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| AU2019366956B2 (en) * | 2018-10-23 | 2025-10-30 | Dragonfly Therapeutics, Inc. | Heterodimeric Fc-fused proteins |
-
2020
- 2020-06-03 BR BR112021024438A patent/BR112021024438A2/pt unknown
- 2020-06-03 CN CN202080055104.6A patent/CN114173822B/zh active Active
- 2020-06-03 CA CA3144535A patent/CA3144535A1/en active Pending
- 2020-06-03 WO PCT/US2020/070113 patent/WO2020247974A1/en not_active Ceased
- 2020-06-03 JP JP2021571671A patent/JP7680375B2/ja active Active
- 2020-06-03 EP EP20818032.3A patent/EP3976111A4/en active Pending
- 2020-06-03 AU AU2020289485A patent/AU2020289485A1/en active Pending
- 2020-06-03 US US17/596,118 patent/US20220298225A1/en active Pending
- 2020-06-03 MX MX2021014932A patent/MX2021014932A/es unknown
-
2025
- 2025-05-08 JP JP2025077691A patent/JP2025121986A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025121986A5 (https=) | ||
| Li et al. | Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL | |
| US6399068B1 (en) | Method of treatment with a non-antigenic toxin-conjugate and fusion protein of internalizing receptor system | |
| US8920777B2 (en) | Toxins and radionuclides coupled to IGF-1 receptor ligands for treatment of cancer | |
| Curnis et al. | NGR-tagged nano-gold: A new CD13-selective carrier for cytokine delivery to tumors | |
| US11697675B2 (en) | EPHA3 and multi-valent targeting of tumors | |
| JP2021502810A5 (https=) | ||
| Mahmoudi et al. | Recombinant immunotoxins development for HER2-based targeted cancer therapies | |
| JPH04503945A (ja) | 血管透過性抱合体 | |
| US20110262466A1 (en) | Compositions containing thrombomodulin domains and uses thereof | |
| HRP20030192A2 (en) | Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target specific prodrug | |
| US20180154012A1 (en) | Cancer immunotherapeutic | |
| Corti | Strategies for improving the anti-neoplastic activity of TNF by tumor targeting | |
| She et al. | Snoopligase-catalyzed molecular glue enables efficient generation of hyperoligomerized TRAIL variant with enhanced antitumor effect | |
| JPWO2020247974A5 (https=) | ||
| JPWO2020168110A5 (https=) | ||
| JPWO2022190018A5 (https=) | ||
| JPWO2022236292A5 (https=) | ||
| Liu et al. | Improvement of tumor targeting and antitumor activity by a disulphide bond stabilized diabody expressed in Escherichia coli | |
| WO2017147820A1 (zh) | 双重标靶药物载体 | |
| US11952402B2 (en) | Fusion protein containing trail and IgG binding domain and the uses thereof | |
| JPWO2022079161A5 (https=) | ||
| US20250382360A1 (en) | Anti-VEGF Single Chain Variable Fusion Protein (RNAT82) | |
| US20250381288A1 (en) | Anti-VEGF Single Chain Variable Fusion Protein (RNAT92) | |
| CA2930243C (en) | Epha3 and multi-valent targeting of tumors |